Single-arm phase IIIB trial of Durvalumab in combination with Platinum-Etoposide for patients with extended-stage small cell lung cancer who have not received treatment, reflecting real clinical practice in Spain (CANTABRICO).
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: ASTRAZENECA FARMACEUTICA ESPAÑA SA
- Phase: IIIb
- Execution start: 18/11/2020
- End of execution: 30/05/2022
- IP: VICTOR AMEZCUA HERNANDEZ